Journal of Iso topes

14 2 2001 5 Journal of Iso topes V o l. 14 N o. 2 M ay 2001 (, 510120) :, : ; ; : R 81718; R 97911; R 738 : A : 100027512 (2001) 0220107208, 85%, 80% [ 1, 2 ],,,,,, 90% 1, ; ;, ( ) [ 2 4, ] : Β ; ;, [ 5 7 ],, : 2000208215; : 2001201203 : (1954 ), ( ),,,

108 14 2, 32 P 89 Sr 153 Sm 186 R e 188 R e, 1,, (Β ), Χ, 1 Β gm ev gmm 32 P 14. 2 d 1. 71 8. 0 89 Sr 50. 6 d 1. 49 6. 7 90 Y 2. 7 d 2. 27 11. 0 117 Sn m 13. 6 d 0. 13 0. 3 153 Sm 46. 3 h 0. 81 3. 4 186 Re 3. 8 d 1. 07 4. 7 188 Re 16. 7 h 2. 12 3. 0 2. 1 2. 1. 1, ;,,, 2. 1. 2,,, 2. 1. 3 89 Sr 32 P Β,,, 0. 8 2. 0 M ev ; 1 cm 2. 1. 4 : 2. 2,,,, 2. 2. 1 : ; ( ), ; ( ) 3. 5 10 9 gl, 80 10 9 gl ; 3 2. 2. 2 : ;

2 : 109 ; ; ; g, g 2. 3 21311 3, X 2. 3. 2, [ 8 4 5 ] ( ) 4 5 2. 3. 3 3 5, 3, g ( ) :,,, g ; g ( ) :, ; g ( ) :, 2. 4,,,,,,,,, ( ) Co lem an [ 9 ], 16 (3 ) X, 12,, ; 2 ; 1 6,,,, 1, 16 15 ; 23 5, 3 g,, 3 6, 3 3. 1 32 P 32 P : 32 P2, Β, DNA ; 32 P 32 S, DNA, DNA DNA, ;, 5, Β,, ; 1950, F riedell [ 10 ]

110 14 32 P, 12 10, 32 P, 32 P, 32 P2, Β,, 32 P [ 11, 12 ], 3. 2 89 Sr-SrCl2 3. 2. 1 89 Sr Β Sr Ca,,,, 89 Sr 10%, ; 48 h, 10%, 2 25, 89 Sr, 90, 20% 88%,, 89 Sr,,,, 89 Sr (PEG),,, 3. 2. 2 89 Sr 89 Sr,, 79% 92% 89 Sr 89 Sr, 80% 89%, 10% 18% 89 Sr 89 Sr,, Β,, 89 Sr 89 Sr, Po rter [ 13 ], 89 Sr 2 Q u ilty [ 14 ], 89 Sr 63. 9%, 41. 7% Q u ilty, 89 Sr 89 Sr, 89 Sr,,, 89 Sr, 89 Sr,, X 89 Sr 3. 2. 3 89 Sr 1. 48 2. 22 M Bq (40 60 ΛC i) gkg, 111 148 M Bq 2. 22 2. 96 M Bq (60 80 ΛC i) gkg 2. 035 3. 145M Bq (55 85 ΛC i) gkg, K lo iber [ 15 ], 740 M Bq 89 Sr L aing [ 16 ],,, 1. 5 M Bqgkg, 1. 5 M Bqgkg 3. 2. 4 [ 16, 17 ], 5% 10%, 89 Sr, 5 10 d, 2 4 d,

2 : 111 3. 2. 5 89 Sr, 89 Sr, 89 Sr 3 Rob in son [ 18 ] 89 Sr, 3. 2. 6,, 89 Sr Po rter [ 13 ], 89 Sr,,, 89 Sr,,,, 89 Sr, 3 89 Sr 313 186 Re-HED P 186 R e 92 h, 137 kev Χ, 1. 07 M ev (77% ) 0. 934 M ev (23% ) Β M axon [ 19 ] 1 100 1 295 M Bq (30 35 m C i) 186 R e2h ED P, 0. 75 Gy, 10 140 Gy 20, 5, 11, 80% 1, 7 8 L iepe [ 20 ] 186 R e 89 Sr, 3. 4 188 Re-HED P 188 R e 17 h, 2. 12M ev, 3 mm ; Χ 155 kev, M axon [ 21 ] 188 R e2h ED P 8, 72. 6 5. 1 7, 1 8 3, 5 5 186 R e2h ED P 1 262 33. 3 M Bq (34. 1 0. 9 m C i), 3, 2 3 1 817 85 M Bq (49. 1 2. 3 m C i) 186 R e2h ED P, 1, ; 1 36% ; 1, 22% L iepe [ 20 ], 188 R e,,,,, 2 3. 5 153 Sm -ED TM P FDA 153 Sm 2ED TM P 153 Sm, 46. 3 h, Β 0. 805 M ev (20% ) 0. 710 M ev (50% ) 0. 640 M ev (30% ), 225 kev Β (3. 4 mm ), 153 Sm 103 kev (29. 8% ) Χ, T u rner [ 22 ], 153 Sm 2ED TM P,

112 14 87%, 4 40, 8, 4 52, 24 [ 23 ] 153 Sm 2ED TM P 300 ( 182, 118 ), 110, 40, 30, 20, 50 50 18. 5 37 M Bqgkg, 7. 9 6. 8, 2 26 136 ( 81, 55 ), 49, 77 ; Karnofsky 10. 5 (5 25 ) ; 55 2. 1 h (1 5 h) ; 30 153 Sm 2ED TM P 90% T u rner [ 22 ] 34 153 Sm 2ED TM P, 14 X L attim er [ 24 ] 99 T c m 2M D P 153 Sm, 1 6 ;,, 9, [ 25 ] 14. 8 29. 6 M Bq (0. 4 0. 8 m C i) gkg, 92. 7% (38g41),, 6 104, 153 Sm 2ED TM P 45, 59 ; 1 14 153 Sm 2ED TM P 300, 29, 51, ; 154 6, 101, 45, 10 8 3. 6 90 Y - 90 Y 90 Sr, 64. 1 h, Β, 2. 27 M ev Ku tzner [ 26 ] 90 Y, 90 Y 80% 90 Y 87 Sr m 87 Y Χ 0. 48 0. 39M ev,, Ku tzner 90 Y 16, 532. 8M Bq (14. 4 m C i), [ 6, ] 90 Y2ED TM P 72, 156, 77. 4% 90 Y 90 Sr2 90 Y,, Β, 3. 7 117 Sn m -D TPA 117 Sn m 2D T PA :, 117 Sn m 13. 6, 127 156 kev Β [ 27 158. 61 kev Χ, Χ ] 117 Sn m 153 Sm 186 R e, 116 Sn 117 Sm m 2D T PA, 117 Sn m 2D T PA ; 117 Sn m 2D T PA ( 153 Sm 2ED TM P), 3 117 Sn m 2D T PA,, g, 8. 98, 10. 9 117 Sn m 0. 3 mm,, 117 Sn m 2D T PA 99 T c m 2M D P,

2 : 113 117 Sn m 2D T PA 3. 8 131 I-BD P3 131 I 8. 03, Β 0. 605 (90. 4% ) 0. 333 (6. 9% )M ev, Χ 364 (82% ) kev E isenhu t [ 28 ] 131 I, Α2 ( 2 ) (BD P3) 131 I2BD P3 : 4 h 50% 131 I2BD P3 :,, 0. 5% 18, 44%, 6%, 22%, 28% 131 I, 4, : ; ( ) ; ; ; ; ;,, ;, ;, : [ 1 ] L o te K,W alloe A, B jersand A. Bone M etastasis, P rogno sis, D iagno sis and T reatm ent[j ]. A cta R adio l O nco l, 1986, 25 (4 6): 227 232. [2 ] Garretj IR. Bone D estruction in Cancer[J ]. Sem in O nco l, 1993, 20 (3 Supp l 2): 4 9. [ 3 ] N ielsen O S, M unro A J, T annock IF. BoneM etastases: Pathophysio logy andm anagem ent Po licy[j ]. J C lin O nco l, 1991, 9: 509 524. [4 ] Fo ley K. Pain Syndrom es in PatientsW ith Cancer[J ]. M ed C lin N o rth Am, 1987, 71: 169 184. [5 ],,,. 153 Sm 2ED TM P [J ]., 1992, 12: 248 249. [6 ],,,. 90 Y2ED TM P [J ]., 1995, 5: 290 292. [7 ] Ho sk in PJ. Scientific and C linicala spects of R adio therapy in the R elief of Bone Pain [J ]. Cancer Surv, 1988, 7 (1): 69 86. [8 ]. [M ]. :, 1997. [ 9 ] Co lem an R E, M ash iter G,W h itaker KB, et al. Bone Scan F lare P redicts Successful System ic T herapy fo r Bone M etases[j ]. J N uclm ed, 1988, 29: 1 354 1 359. [10 ] F riedell HL, Sto rassli JP. T he U se of R adioactive Pho spho rus in the T reatm ent of Cancinom a of the B reast W ith W idesp read M etastases to Bone[J ]. Am e J Roentgeno l, 1950, 64: 559 575. [ 11 ] Silberstein EB. T he T reatm ent of Painful O sseous M etastases W ith Pho spho rus2322labeled Pho s2 phates[j ]. Sem in O nco l, 1993, 20 (3 Supp l 2): 10 21. [12 ] V an N o strand D, Silberstein EB. T herapeutic U ses of 32 P [A ]. F reem an LM, W eissm an H S. N uclear M edicine A nnual [C ]. N ew Yo rk: R aven P ress, 1985. 289 344. [ 13 ] Po rter A T, M cew an A JB, Pow e JE, et al. R esults of a R andom ized Phase2g T rial to Evalute the Ef2 ficacy of Steontium 289 A djuvant to L ocal F ield External Beam Irradiation in the M anagem ent of En2 docrine R esistant M etastatic P ro state Cancer[J ]. Int J R adiation O nco logy B io l Phys, 1993, 25: 805 813.

114 14 [ 14 ] Q uilty PM, K irkd, Bo lger JJ, et al. A comparison of the P slliative Effects of Strontium 289 and Exter2 nal Beam R adio therapy in M etastatic P ro state Cancer[J ]. R adio therapy and O nco logy, 1994, 31 (1): 33 40. [ 15 ] K lo iber R, M o lnar CP, Barnes M. Sr289 T herapy fo r M etastatic Bone D isease: Sintograph ic and R a2 diograph ic Fo llow 2up [J ]. R adio l, 1987, 163: 719 723. [16 ] L aing A H, A ckery DM, Bayly RJ, et al. Strontium 289 Ch lo ride fo r Pain Palliation in P ro static Skele2 talm elignancy[j ]. B ritish J R adio logy, 1991, 64: 816 822. [17 ],,,. 89 Sr [J ]., 1997, 17: 628 630. [ 18 ] Robinson R G, P reston D F, Sch iefelbeinm, et al. Strontium 289 T herapy fo r the Palliation of Pain D ue to O sseousm etastases[j ]. JAM A, 1995, 274: 420 424. [ 19 ] M axon HR 3d, Sch roder L E, R ertsberq V S, et al. R henium 2186 (Sn) 2H ED P fo r T reatm ent of Painful O sseous M etastases: R esults of Doule2blind C ro ssover Comparison W ith P lacebo [J ]. J N ucl M ed, 1991, 32: 1 877 1 881. [20 ] L iepe K, K ropp J, Knapp FJ, et al. R heniun2188 in Comparison to R henium 2186 and Strontium 289 in the T reatm ent of Bone M etastases[j ]. Eur J N uclm ed, 1998, 25 (8): 861. [21 ] M axon HR 3d, Sch roder L E, W ashburn L C, et al. R henium 2188 (Sn) H ED P fo r T reatm ent of O s2 seousm etastaseṡ J N uclm ed, 1998, 39 (4): 659 663. [22 ] T urner JH, M artindal AA, So rby P, et al. Sam arium 21532ED TM P T herapy of D issem inated Skeletal M etastases[j ]. Eur J N uclm ed, 1989, 15: 784 796. [23 ] D eng H F, T an T Z, Hou CL, et al. A R adiopharm aceutical fo r Bone T umo r T herapy[j ]. J N uclm ed, 1997, 38 (5): 252. [ 24 ] L attim er JC, Co rw in J r LA, Stap leton J, et al. C linical and C linicopatho logic R esponse of Canin Bon Bone T umo r Patients to T reatm ent W ith Sam arium 21532ED TM P [J ]. J N ucl M ed, 1990, 31: 1 316 1 325. [25 ],,,. 153 Sm 2ED TM P [J ]., 1994, 14: 211 213. [ 26 ] Kutzner J, D ahnert W, Sch reger T, et al. Y ttrium 290 Zur Schm erztherap ie V on Knochem etastasen [J ]. N uclm ed, 1981, 20: 229 235. [27 ] K rishnam urthy GT, Sw ailem FM, Srivastava SC, et al. T in2117m (4+ )D T PA : Pharm acok inetics and Im aging Characteristics in PatientsW ith M etastatic Bone Pain [J ]. J N uclm ed, 1997, 38: 230 236. [28 ] E isenhut M. Iodine21312labeled D ipho sphonates fo r the Palliative T reatm ent of Bone M etastases: I O rgan D istribution and K inetics of I2131 BD P3 in R ats[j ]. J N uclm ed, 1984, 25: 1 356 1 361. Recen t D evelopm en t of Trea ting Bone M a ta sta ses W ith Rad iopharmaceutica ls J IAN G N ing2yi (M em orial H osp ital S un Y at2sen U niversity of M ed ical S ciences, Guang z hou, 510120, Ch ina) Abstract: Pain palliation w ith bone2seek ing radiopharm aceu ticals is an effective and co steffec2 tive m anagem en t too l in patien ts w ith advanced cancer m etastatic to bone. T he recen t devel2 opm en ts in bone m atastastic disease m anagem en t w ith radiopharm aceu ticals is discribed. T he m echan ism s, characteristics, u sages, clin ical values as w ell as advan tages and disadvan tages are all review ed, at the sam e tim e, the direction of fu rther study is p ropo sed. Key words: radionuclide therapy; bone m atastastic cancer; cu rative effect